Platinum-resistant cancer treatment
AssigneeBTG International Limited
InventorUdai BANERJI
Life of this patent
Estimating the term…
Abstract
A compound of formula I or a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration. Method of treatment and novel dosage forms are also provided. Particularly treated are ovarian cancers, particularly those expressing α-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.
Claims21
1-100. (canceled)
A method of treating cancer in a patient in need thereof comprising administering to the patient a compound chosen from compounds of formula I
- compounds of formula II
- and pharmaceutically acceptable salts or esters thereof, wherein:
- the cancer has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy, and
- the treatment is with a dose that achieves a blood concentration of about 0.5 μM or greater of the compound for at least 72 hours.
Dependencies are inferred from the claim text.